Response to high-dose imatinib mesylate following resistance/relapse to standard-dose imatinib mesylate
| Resistance/relapse status . | Median time on 400 mg imatinib mesylate, mo (range) . | Patients treated, no. . | Patients with CHR/with PHR, no. . | Patients with CG response, no. . | ||
|---|---|---|---|---|---|---|
| CR . | PR . | Minor . | ||||
| Loss of CG CR or CG PR | ||||||
| Ph exceeding 90% | 19 (14-26) | 3 | NA | 0 | 0 | 1 |
| Ph 35% to 90% | 21 (12-27) | 6 | NA | 3 | 2 | 0 |
| Loss of minor CG response to 100% Ph+ | 18 (15-25) | 4 | NA | 1 + 1* | 0 | 1 + 1* |
| CG resistance | ||||||
| Ph exceeding 90% | 12 (12-23) | 14 | NA | 0 | 1* | 2 + 1* |
| Ph 35% to 90% | 17 (12-25) | 7 | NA | 1 | 4 | 0 |
| Any CG resistance/relapse | 17 (12-27) | 34 | NA | 5 + 1* | 6 + 1* | 4 + 2* |
| Hematologic relapse | 12 (4-22) | 14 | 6/4 | 0 | 0 | 1 |
| Hematologic resistance | 5 (2-14) | 6 | 3/0 | 0 | 1 | 0 |
| Resistance/relapse status . | Median time on 400 mg imatinib mesylate, mo (range) . | Patients treated, no. . | Patients with CHR/with PHR, no. . | Patients with CG response, no. . | ||
|---|---|---|---|---|---|---|
| CR . | PR . | Minor . | ||||
| Loss of CG CR or CG PR | ||||||
| Ph exceeding 90% | 19 (14-26) | 3 | NA | 0 | 0 | 1 |
| Ph 35% to 90% | 21 (12-27) | 6 | NA | 3 | 2 | 0 |
| Loss of minor CG response to 100% Ph+ | 18 (15-25) | 4 | NA | 1 + 1* | 0 | 1 + 1* |
| CG resistance | ||||||
| Ph exceeding 90% | 12 (12-23) | 14 | NA | 0 | 1* | 2 + 1* |
| Ph 35% to 90% | 17 (12-25) | 7 | NA | 1 | 4 | 0 |
| Any CG resistance/relapse | 17 (12-27) | 34 | NA | 5 + 1* | 6 + 1* | 4 + 2* |
| Hematologic relapse | 12 (4-22) | 14 | 6/4 | 0 | 0 | 1 |
| Hematologic resistance | 5 (2-14) | 6 | 3/0 | 0 | 1 | 0 |
CG indicates cytogenetic; CG CR, complete cytogenetic response; CG PR, partial cytogenetic response; and NA, not applicable.
Analysis by fluorescent in situ hybridization.